Fig. 3

Enhanced tumor volume reduction results from using multiple mRNA-1273 IT injections. B16F10 (A) tumor growth curves and (B) survival curves following three 20 µL IT injections of 3 µg mRNA-1273, empty LNP or PBS (n = 5 mice treated with mRNA-1273 and LNP, n = 3 mice treated with PBS, n = 13 mice total); hazard ration (HR) of mRNA-1273/LNP is 0.043 with log-rank (Mantel-Cox) test, **p = 0.0035, HR of mRNA-1273/PBS is 0.024 with log-rank (Mantel-Cox) test, **p = 0.0082 and HR of LNP/PBS is 0.16 with log-rank (Mantel-Cox) test, p > 0.5. (C) B16F10 tumor volume measurements at 8 days post IT injection comparing three doses of mRNA-1273 versus a single mRNA-1273 IT dose (single dose mRNA-1273 IT data is same dataset as shown in Fig. 2C, n = 5 mice/group, n = 10 mice total). Abscopal effects of mRNA-1273 was evaluated using mice implanted with tumors on the right and left flanks. (D) B16F10 tumor volume measurements of treated right and untreated left flank tumors at day 8 post IT injection using three 20 µL IT injections of 3 µg mRNA-1273 or PBS (n = 5 mice treated with mRNA-1273 and n = 3 mice treated with PBS, n = 8 mice total). Data shown as mean (SD); unpaired student t test or two-way ANOVA followed by Tukey’s multiple comparison test, *p < 0.05, **p < 0.01, ***p < 0.001.